Purpose: This research aimed to determine the impacts of early medication of hydroxychloroquine, favipiravir, or both drugs from the emergency room (ER) on hospitalization, mortality, and length of stay (LoS) in hospital. Material-method: This research is a retrospective, crosssectional and descriptive study that includes the period between 01.11.2020 and 30.11.2020. The patients were divided into three groups according to the drugs they used. Results: During the study period, 34299 cases applied to the ER with Covid-19 symptoms. The Covid-19 reverse transcription polymerase chain reaction (Rt-PCR) test of 14469 (42.2%) patients was positive. Rt-PCR was positive in 3724 (60.1%) of 6202 medicated patients in the ER; moreover, 99 (1.6%) of them were hospitalized at their subsequent admission. Of inpatients, 21 (21.2%) died, 78 (78.8%) were discharged. There was no significant difference between hospitalized patients in terms of service or intensive care admission, mortality status, LoS in hospital. Mortality rate was; 0.2% in Group 1, 0.7% in Group 2, 1.1% in Group 3. The LoS in hospital according to the groups was 5.6 days, 7.9 days, and 7 days, respectively. Conclusion: Among the mildly symptomatic Covid-19 patients, the group using hydroxychloroquine alone was less hospitalized than the patient groups using other drugs. According to their drugs, there was no significant disparity between hospitalized patient groups in terms of mortality status or LoS in hospitals.